当前位置:首页 - 行情中心 - 恒瑞医药(600276) - 财务分析

恒瑞医药

(600276)

  

流通市值:3255.84亿  总市值:3255.84亿
流通股本:63.79亿   总股本:63.79亿

恒瑞医药(600276)财务分析

净利润 + 每股收益
------
  • 净利润(亿元)
  • 每股收益(元)

    截至2024年年度实现净利润63.37亿元,每股收益1.00元。

股东权益 + 未分配利润
------
  • 股东权益(亿元)
  • 未分配利润(亿元)

    截至2024年年度最新股东权益4609025.07万元,未分配利润3386552.90万元。

总资产 + 负债
------
  • 总资产(亿元)
  • 负债(亿元)

    截至2024年年度最新总资产5013564.53万元,负债404539.46万元。

利润表
报告期2024-12-312024-09-302024-06-302024-03-31
营业总收入27,984,605,342.0620,189,303,845.113,600,734,114.775,997,533,912.14
营业总成本21,008,000,532.0315,089,979,241.89,756,000,390.114,412,916,241.65
营业利润7,490,632,003.885,345,290,528.733,984,776,115.541,636,008,814.62
利润总额7,169,689,995.755,086,740,155.233,751,600,104.871,502,510,834.52
净利润6,336,994,647.534,616,330,177.463,428,132,358.041,367,488,687.72
其他综合收益-624,026.11-12,630,993.15-17,226.74-5,925,391.68
综合收益总额6,336,370,621.424,603,699,184.313,428,115,131.31,361,563,296.04
资产负债表
报告期2024-12-312024-09-302024-06-302024-03-31
流动资产合计35,314,927,240.5934,456,969,388.1634,776,635,798.2633,712,251,970.65
非流动资产合计14,820,718,063.5113,881,130,024.5613,404,724,245.3112,627,749,380.19
资产总计50,135,645,304.148,338,099,412.7248,181,360,043.5746,340,001,350.84
流动负债合计3,633,595,722.673,829,566,410.174,808,305,486.213,698,071,656.15
非流动负债合计411,798,848.12177,014,307.13185,918,401.38202,574,392.61
负债合计4,045,394,570.794,006,580,717.34,994,223,887.593,900,646,048.76
归属于母公司股东权益合计45,519,861,860.3243,767,908,821.7542,622,242,805.0841,873,504,779.57
股东权益合计46,090,250,733.3144,331,518,695.4243,187,136,155.9842,439,355,302.08
负债和股东权益合计50,135,645,304.148,338,099,412.7248,181,360,043.5746,340,001,350.84
现金流量表
报告期2024-12-312024-09-302024-06-302024-03-31
经营活动现金流入小计28,468,881,744.1320,546,797,062.713,838,319,569.276,136,051,366.98
经营活动现金流出小计21,046,128,705.4215,961,351,053.5810,805,564,728.094,881,452,457.98
经营活动产生的现金流量净额7,422,753,038.714,585,446,009.123,032,754,841.181,254,598,909
投资活动现金流入小计679,892,183.13251,221,022.4541,081,305.0610,631,618.06
投资活动现金流出小计2,591,877,899.362,124,667,512.241,564,673,726.04761,021,859.6
投资活动产生的现金流量净额-1,911,985,716.23-1,873,446,489.79-1,523,592,420.98-750,390,241.54
筹资活动现金流入小计799,909,380.08799,909,380.08799,909,380.08-
筹资活动现金流出小计2,350,499,405.962,306,433,430.14938,476,900.9618,134,576.37
筹资活动产生的现金流量净额-1,550,590,025.88-1,506,524,050.06-138,567,520.88-18,134,576.37
汇率变动对现金及现金等价物的影响7,400,551.34-21,219,513.59-5,838,450.66-18,208,185.01
现金及现金等价物净增加额3,967,577,847.941,184,255,955.681,364,756,448.66467,865,906.08
期末现金及现金等价物余额24,239,102,117.6621,455,780,225.421,636,280,718.3820,739,390,175.8
最新报告期:2025-04-01
研究机构分析师预测每股收益(元)更新日
2024年2025年2026年
群益证券王睿哲1.091.371.632025-04-01
中信证券陈竹,韩世通1.161.341.552025-04-01
光大证券叶思奥,王明瑞1.071.261.442025-04-01
民生证券王班,王维肖1.141.341.612025-04-01
国海证券万鹏辉1.111.271.462025-04-01
TOP↑